Objectives: We investigated the efficacy and safety of a complex (ALAVAX) of
5-aminolevulinic acid (5-ALA) and glycyl-histidyl-lysine (GHK) peptide for the treatment of pattern hair loss.
Introduction: Pattern hair loss is a very common problem. Although effective therapeutics for the treatment of pattern hair loss have been used, novel therapeutic modalities are still required to enhance hair growth.
Materials / method: Forty-five patients with male pattern hair loss were treated with ALAVAX 100 mg/ml (group A), ALAVAX 50 mg/ml (group B) or placebo (group C) once a day for 6 months. Total hair count, hair length, hair thickness, patient’s assessment and adverse events were evaluated at month 1, 3, and 6.
Results: An increase in hair count for 6 months was 52.6 (p<0.05) in group A, 71.5 (p<0.05) in group B, and 9.6 in group C. The ratio of changes in hair count between group B (2.38) and group C (1.21) at 6 months showed a statistically significant difference (p<0.05). The proportion above good satisfaction was higher in group A (26.7%) than in the other
groups (group B: 14.3%, group C: 7.1%). There was no statistically
significant difference in hair length and hair thickness among 3 groups at 6 months. There was no adverse event in 3 groups.
Conclusion: Our study showed that a complex of 5-ALA and GHK peptide may be considered as one of the complementary agents for the treatment of male pattern hair loss.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
否
您是否接受过关于这项研究的任何酬金或其他报酬?
否
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
否
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。